# PRospective REgistry of Advanced Stage CancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine

> **NCT05697198** · — · COMPLETED · sponsor: **Labcorp Corporation of America Holdings, Inc** · enrollment: 1429 (actual)

## Conditions studied

- Lung Cancer
- Ovarian Cancer
- Uterine Cancer
- Colorectal Cancer
- Stomach Cancer
- Esophageal Cancer
- Pancreatic Cancer
- Melanoma
- Breast Cancer
- Head and Neck Cancer
- Soft Tissue Sarcoma
- Rhabdomyosarcoma
- Prostate Cancer

## Interventions

- **DIAGNOSTIC_TEST:** OmniSeq Test

## Key facts

- **NCT ID:** NCT05697198
- **Lead sponsor:** Labcorp Corporation of America Holdings, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-19
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 1429 (ACTUAL)
- **Last updated:** 2025-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05697198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05697198, "PRospective REgistry of Advanced Stage CancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05697198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*